NANOG and hepatocellular carcinoma: A study found that the homeobox transcription factor NANOG inhibited mitochondrial OXPHOS and activated FAO through the TLR4/E2F1/NANOG pathway, promoting resistance of HCC TIC to sorafenib [125].